Samsung BioLogics to produce Pfizer's COVID-19 vaccine - report
The biotech arm of Samsung Group has been revamping production lines at its plant in Songdo to produce the Pfizer vaccine, which was jointly developed by BioNTech, the Korea Economic Daily said. The plant can make up to 1 billion doses per year, the report said, quoting an unnamed high-level government official.
- Country:
- South Korea
Samsung BioLogics Co Ltd is in talks with Pfizer Inc to begin production of the U.S. drugmaker's COVID-19 vaccine in South Korea as early as in August, a South Korean newspaper reported on Wednesday. The biotech arm of Samsung Group has been revamping production lines at its plant in Songdo to produce the Pfizer vaccine, which was jointly developed by BioNTech, the Korea Economic Daily said.
The plant can make up to 1 billion doses per year, the report said, quoting an unnamed high-level government official. Samsung BioLogics and Pfizer were not immediately available for comment. The Korea Disease Control and Prevention Agency (KDCA) in charge of COVID-19 vaccine procurement was also not immediately available for comment.
South Korea has a contract with Pfizer to purchase 66 million doses of its COVID-19 vaccine. It also has contracts to acquire a total of 192 million doses from other developers including Moderna Inc, AstraZeneca Plc, Johnson & Johnson's and Novavax.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Ten years after South Korean ferry disaster, mothers express their grief on stage
Health News Roundup: Abortions in first 12 weeks should be fully legalised in Germany, commission says; Novavax investor Shah Capital calls for two independent directors and more
South Koreans still seek answers 10 years after Sewol ferry disaster
Health News Roundup: WHO warns of falsified cough syrup ingredients seized in Pakistan; Novavax investor Shah Capital pushes for board shakeup and more
South Korean court hears children's climate change case against government